These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 16722814)

  • 1. Albumin-bound paclitaxel: a next-generation taxane.
    Gradishar WJ
    Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin-bound Paclitaxel: in metastatic breast cancer.
    Robinson DM; Keating GM
    Drugs; 2006; 66(7):941-8. PubMed ID: 16740010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F; Borgonovo K; Barni S
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
    Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. nab-Paclitaxel mechanisms of action and delivery.
    Yardley DA
    J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration.
    Chen N; Brachmann C; Liu X; Pierce DW; Dey J; Kerwin WS; Li Y; Zhou S; Hou S; Carleton M; Klinghoffer RA; Palmisano M; Chopra R
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):699-712. PubMed ID: 26231955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
    Guarneri V; Dieci MV; Conte P
    Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
    Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
    Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
    Henderson IC; Bhatia V
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ; Soon-Shiong P; Desai N
    Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
    Jain MM; Gupte SU; Patil SG; Pathak AB; Deshmukh CD; Bhatt N; Haritha C; Govind Babu K; Bondarde SA; Digumarti R; Bajpai J; Kumar R; Bakshi AV; Bhattacharya GS; Patil P; Subramanian S; Vaid AK; Desai CJ; Khopade A; Chimote G; Bapsy PP; Bhowmik S
    Breast Cancer Res Treat; 2016 Feb; 156(1):125-34. PubMed ID: 26941199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
    Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
    J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
    Ando M; Yonemori K; Katsumata N; Shimizu C; Hirata T; Yamamoto H; Hashimoto K; Yunokawa M; Tamura K; Fujiwara Y
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):457-65. PubMed ID: 21853310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
    Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
    Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
    Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
    Lipp HP
    Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
    Gardner ER; Dahut WL; Scripture CD; Jones J; Aragon-Ching JB; Desai N; Hawkins MJ; Sparreboom A; Figg WD
    Clin Cancer Res; 2008 Jul; 14(13):4200-5. PubMed ID: 18594000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.